Replies to post #14865 on NDT Pharmaceuticals Inc (NDTP)

[Ecomike]

Actually it is no longer really empty.

NV-State Judge already closed the Custodian case and issued the exit order approval for the custodian to exit MILV as a custodian, after naming the new directors and officers at the Nevada SOS, and resigning.

James Hovis already put out his neck in on the line by naming himself as the CEO of MILV on OTC markets weeks ago.

The custodian already returned 66% of the OS shares he took for control late last year to the treasury, which was reported by the new, current transfer agent weeks ago on OTCmarkets. Only one reason he would do that!!!!

He upped his remaining share cost 300% by doing that and gave up 2/3rds of shares back to the company. Why did he do that?

Who does that and why?

I said that would happen last year and it did, 66% of it did. I also predicted the custodian would return the rest of them by trading them to the CCA, LLC Biotech asset holding shareholders for cash, and he would be history, leaving the CCA, LLC asset biotech shares holders with MILV shares traded for the biotech assets they are bringing in, as they pay the custodian with cash and or preferred shares for the rest of the restricted shares.

I think they will swap them for preferred shares, bringing the 290 Mil share float back to being 100% of the OS and use the transaction to add to book asset value for the Biotech to the books. Or some such version of that.

Days ago the attorney listed his name on OTC markets showing MILV/CCA, LLC hired him to do the last step and do an SEC S-1 filling to go fully SEC reporting.

Here is what I see coming.

Nevada Officer and directors listed and the annual fees and annual list update by May31 st. The new attorney just named days ago on OTCmarkets, preparing an S-1/super 8-K with two 10-K fillings and a copy of the transferred UPennMed JV contract, the officers and directors details and the business history and entire plan for the new MILV now known as NDT Pharmaceuticals Inc.

Then the website going live, and then PRs and I am now 99% sure a drink line launch (probably distributed by PepsiCo is my bet) first as the revenue source up front, and then the Biotech licensing of the #TBI #NDT Biotech that is being brought to MILV by R/M

I also have a gigabyte of files going back 40 years connecting the dots leading up to this Biotech launch, that tells me an oral IV drink (not hospital, not needle, no drip bag) is coming that can reduce and or limit #TBI and Alzheimers based dementia in the brain that will not need FDA approval as the ingredients are all GAAS Generally Accepted AS Safe by the FDA already and that includes Phosphotidyl-Choline liposomes as well. The key here is that "Size Matters"

If one could do private investments in what is coming to MILV, this would be one of the best private Biotech investments I have seen in my life time. Lucky for us we can in early with publicly traded shares. That may explain why 5+ millionaires have been funding the firm R/M with MILV since 2013.

I am not selling, I am buying and adding.